Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Single Dose Study of PF-05230907 in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-05230907
Drug: Placebo

First Posted Date: 2015-09-01

Last Posted Date: 2016-04-29

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT02537002

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study Comparing Amounts of Tafamidis In The Blood With Or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tafamidis

First Posted Date: 2015-08-28

Last Posted Date: 2015-12-22

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT02534740

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Phase 2

Completed

Conditions: Meningococcal B Disease

Interventions: Biological: rLP2086 vaccine
Biological: Pediatric HAV vaccine

First Posted Date: 2015-08-28

Last Posted Date: 2021-09-27

Lead Sponsor: Pfizer

Target Recruit Count: 396

Registration Number: NCT02534935

Locations: 🇦🇺
The Canberra Hospital, Canberra, Garran, Australian Capital Territory, Australia
🇦🇺
Vaccine Trials Group, Telethon Kids Institute, Perth Children's Hospital, Nedlands, Western Australia, Australia
🇦🇺
Australian Clinical Research Network (ACRN), Maroubra, New South Wales, Australia

and more 22 locations

Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2015-08-26

Last Posted Date: 2017-10-05

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT02533258

Dose Escalation Study of PF-06741086 In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: PF-06741086
Drug: Placebo

First Posted Date: 2015-08-25

Last Posted Date: 2016-08-12

Lead Sponsor: Pfizer

Target Recruit Count: 41

Registration Number: NCT02531815

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

Phase 2

Completed

Conditions: MENINGOCOCCAL INFECTION

Interventions: Biological: Bivalent rLP2086 Vaccine
Biological: Licensed pediatric hepatits A vaccine
Other: Normal Saline

First Posted Date: 2015-08-24

Last Posted Date: 2020-10-26

Lead Sponsor: Pfizer

Target Recruit Count: 400

Registration Number: NCT02531698

Locations: 🇵🇱
Niepubliczny Zaklad Lecznictwa Ambulatoryjnego "Michalkowice"Jarosz i Partnerzy Spolka Lekarska, Siemianowice Slaskie, Poland
🇫🇮
Espoo Vaccine Research Clinic, Espoo, Finland
🇫🇮
Tampere Vaccine Research Clinic, Tampere, Finland

and more 12 locations

A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis

Phase 4

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Celecoxib 200 milligrams
Drug: Celecoxib 400 milligrams
Drug: diclofenac 50 milligrams

First Posted Date: 2015-08-19

Last Posted Date: 2015-08-19

Lead Sponsor: Pfizer

Target Recruit Count: 330

Registration Number: NCT02528201

Locations: 🇳🇴
Rikshospitalet, Oslo, Norway
🇳🇴
Økernlegene, Oslo, Norway
🇳🇴
Bekkestua legesenter, Bekkestua, Norway

and more 24 locations

A Phase 3 Study of Tanezumab for Chronic Low Back Pain

Phase 3

Completed

Conditions: Low Back Pain

Interventions: Biological: Tanezumab 10 mg SC
Biological: Placebo to Week 16; tanezumab 5mg SC
Biological: Placebo to Week 16, tanezumab 10 mg SC
Biological: Tanezumab 5 mg SC
Biological: Tramadol PR oral

First Posted Date: 2015-08-19

Last Posted Date: 2020-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 1832

Registration Number: NCT02528253

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Chicago Anesthesia Pain Specialists, Chicago, Illinois, United States
🇺🇸
Neuro-Pain Medical Center, Fresno, California, United States

and more 252 locations

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

Phase 3

Completed

Conditions: Chronic Pain
Osteoarthritis, Hip
Osteoarthritis, Knee

Interventions: Drug: NSAID
Biological: Tanezumab 2.5 mg
Biological: Tanezumab 5 mg

First Posted Date: 2015-08-19

Last Posted Date: 2020-01-10

Lead Sponsor: Pfizer

Target Recruit Count: 3021

Registration Number: NCT02528188

Locations: 🇺🇸
Chicago Clinical Research Institute Inc., Chicago, Illinois, United States
🇺🇸
Northwestern Memorial Hospital-Arkes Pavilion, Diagnostic Testing Center, Chicago, Illinois, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

and more 482 locations

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Phase 1

Terminated

Conditions: ALK-positive Advanced NSCLC

Interventions: Drug: Crizotinib
Drug: Pembrolizumab

First Posted Date: 2015-07-29

Last Posted Date: 2019-07-01

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT02511184

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy